WO2026003765 - FORMULATIONS OF ANTI-INTERLEUKIN 1 RECEPTOR 1 ANTIBODIES
National phase entry is expected:
Publication Number
WO/2026/003765
Publication Date
02.01.2026
International Application No.
PCT/IB2025/056476
International Filing Date
25.06.2025
Title **
[English]
FORMULATIONS OF ANTI-INTERLEUKIN 1 RECEPTOR 1 ANTIBODIES
[French]
FORMULATIONS D'ANTICORPS ANTI-RÉCEPTEUR 1 DE L'INTERLEUKINE 1
Applicants **
KINIKSA PHARMACEUTICALS, GMBH
Inventors
D'SOUZA, Ajit
XU, Jianwen
Priority Data
63/663,761
25.06.2024
US
63/664,017
25.06.2024
US
63/670,418
12.07.2024
US
63/762,497
24.02.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6739 | |
| EPO | Filing, Examination, Granting | 138189 | |
| Japan | Filing, Examination, Granting | 5006 | |
| South Korea | Filing, Examination, Granting | 9324 | |
| USA | Filing, Examination, Granting | 34890 |
Total:
194,148
Contact Us
Abstract[English]
The present invention provides, among other things, stable formulations comprising an anti- Interleukin 1 Receptor 1 (IL1R1) antibody at a concentration of greater than 80 mg/ml with a pH ranging from 4.4 – 5.7, wherein the amount of HMW species in the formulation increases less than 2% upon storage at 25° C for at least 4 weeks.[French]
La présente invention concerne, entre autres, des formulations stables comprenant un anticorps anti-récepteur 1 de l'interleukine 1 (IL1R1) à une concentration supérieure à 80 mg/ml avec un pH allant de 4,4 à 5,7, la quantité d'espèces HMW dans la formulation augmentant de moins de 2 % lors du stockage à 25 °C pendant au moins 4 semaines.